Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.
about
PP2A: The Achilles Heal in MDS with 5q DeletionEfficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-AnalysisFOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalitiesRole of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.Clinical utility of lenalidomide in the treatment of myelodysplastic syndromesThe relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromesTrisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?Myelodysplastic syndromes, version 2.2015Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.Recent Advances in the 5q- Syndrome.Immunophenotypic, cytogenetic, and mutational characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia.Emerging biological therapies for the treatment of myelodysplastic syndromes.Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization: Defining an Effective Utilization Strategy for Evaluation of Myelodysplastic Syndromes.Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases.Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burdenPersonalized medicine in myelodysplastic syndromes: wishful thinking or already clinical reality?What lies beyond del(5q) in myelodysplastic syndrome?Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes.Dramatic response in the dependency to transfusion after low doses of lenalidomide treatment in a 5q-syndrome patient: a case report.
P2860
Q27690852-BB28D685-1617-4E42-98CA-42FE04954F3BQ33436627-D5460092-68AA-4153-89B6-A6C493997CB6Q33760754-DCE931AA-CFA2-4432-9A05-7B2CD4FA9D5DQ34348631-A742A4F0-B752-47B9-BC39-82541FF32F33Q34783754-7B1B7961-F0AB-45A3-8B38-68BEE88B9840Q35244865-ED0733B1-E6C5-4AC8-B5F6-AE98881D7CB6Q35661305-E1579D01-0230-4841-8450-3F8AD44408E1Q36416338-79EC935F-4225-4BDB-A4E7-963BA2B78897Q38415206-40832E5E-2F8B-4D90-A912-E86C31A1FB2EQ38527837-CAE9A6F7-ED86-4E7E-8073-3AFEF58B2A2CQ38740563-5ACD46BD-C2BF-44FD-A82E-3271C2A33192Q38834981-03BE4101-63A2-438F-8D36-13349EDE694AQ38880077-2A591A68-7431-4557-97D0-7AF265F16A99Q41156034-1963F786-CA4A-4F8A-A26A-B27E5D843D84Q41176344-0FC47B0E-0D6C-4C05-9FB4-5F1C0CF66EEDQ42550078-E6BB39AE-60B8-451C-A8A0-E09D6BBA2698Q42573901-8CFCBBF0-0F02-4E3C-ADC0-3A865B4A395EQ42831488-90AF8682-8657-44CB-B293-E47ACD2C3DE1Q47548041-2735993D-F863-41E7-B66C-B3A2B87F8E17Q49533848-2F7DB370-960C-4173-A092-31CC1FB2222FQ54384826-2AB81CDB-70C4-4BBD-BAF9-4FD5C1A473AD
P2860
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Response to lenalidomide in myelodysplastic syndromes with del
@nl
Response to lenalidomide in my ...... of cytogenetics and mutations.
@en
type
label
Response to lenalidomide in myelodysplastic syndromes with del
@nl
Response to lenalidomide in my ...... of cytogenetics and mutations.
@en
prefLabel
Response to lenalidomide in myelodysplastic syndromes with del
@nl
Response to lenalidomide in my ...... of cytogenetics and mutations.
@en
P2093
P2860
P50
P356
P1476
Response to lenalidomide in my ...... of cytogenetics and mutations
@en
P2093
Andrés Jerez
Carmen Pedro
Dolors Costa
Esperanza Such
Francesc Solé
Isabel Marugán
Jaroslaw Maciejewski
José Cervera
Juan C Cigudosa
M José Larráyoz
P2860
P356
10.1111/BJH.12354
P407
P577
2013-04-25T00:00:00Z